Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.8903
-0.0527 (-5.59%)
Apr 16, 2026, 11:36 AM EDT - Market open
Aprea Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts that cover Aprea Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $4.10, which forecasts a 360.52% increase in the stock price over the next year. The lowest target is $1.20 and the highest is $7.00.
Price Target: $4.10 (+360.52%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aprea Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 0 | 0 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 1 | 1 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $7 | Buy | Reiterates | $7 | +686.25% | Mar 31, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $4 → $1.2 | Strong Buy | Maintains | $4 → $1.2 | +34.79% | Mar 31, 2026 |
| Wedbush | Wedbush | Buy Maintains $11 → $7 | Buy | Maintains | $11 → $7 | +686.25% | Feb 10, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $4 | Strong Buy | Maintains | $5 → $4 | +349.29% | Jan 29, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 → $5 | Strong Buy | Maintains | $20 → $5 | +461.61% | Dec 18, 2025 |
Financial Forecast
Revenue This Year
n/a
from 285.76K
Revenue Next Year
1.64M
EPS This Year
-0.84
from -1.93
EPS Next Year
-0.69
from -0.84
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | n/a | 3.4M | |||
| Avg | n/a | 1.6M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.79 | -0.48 | |||
| Avg | -0.84 | -0.69 | |||
| Low | -0.88 | -0.88 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.